Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
By T. Nomi, M. Sho, T. Akahori, K. Hamada, Atsushi Kubo, H. Kanehiro, Shinji Nakamura, K. Enomoto, H. Yagita, M. Azuma and 1 more. Clinical Cancer Research, 2007
869 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/ac4a7444ec05bb5d475e1d6fc8828a545a0d9ad1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Arlene H. Sharpe
- G. Freeman
- Loise M. Francisco
- V. Kuchroo
- George Coukos
- K. Kaluza
- Jaikumar Duraiswamy
- D. Pardoll
In Oncology
- Arlene H. Sharpe
- G. Freeman
- Loise M. Francisco
- V. Kuchroo
- George Coukos
- E. Wherry
- D. Pardoll
- James L. Riley
Citations in the corpus
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells (2009, background): “PD-L1 is expressed on a wide variety of tumors, and high levels of PD-L1 expression strongly correlate with unfavorable prognosis in several cancers (Dong et al., 2002; Iwai et al., 2002; Strome et al., 2003; Konishi et al., 2004; Thompson et al., 2004; Blank et al., 2005; Hirano et al., 2005; Ohiga”
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T Cell Rejection Function in Tumors (2013, background): “Mechanisms regulating immune activation in cancer progression have been extensively investigated (4-16).”
- PD-L1 Expression in Triple Negative Breast Cancer (2014, neutral): “PD-L1 is not expressed on normal epithelial tissues but is expressed on many cancers including renal cell carcinoma (20, 26), pancreatic cancer (27), ovarian cancer (28), gastric cancer (29), esophageal cancer (30), and hepatocellular carcinoma (31).”